167 related articles for article (PubMed ID: 34741082)
1. Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Wu F; Yu J; Gan H; Zhang H; Tian D; Zheng D
Sci Rep; 2021 Nov; 11(1):21743. PubMed ID: 34741082
[TBL] [Abstract][Full Text] [Related]
2. Mid- to long-term outcomes of initial transjugular intrahepatic portosystemic shunt versus anticoagulation for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Huang Q; Zhang Q; Xu H; Zu M; Xiao J; Shen B
Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):445-452. PubMed ID: 36719828
[TBL] [Abstract][Full Text] [Related]
3. [Study of PA-HSOS severity grading to predict the prognosis of patients with PA-HSOS treated by transjugular intrahepatic portosystemic shunt].
Chen YR; Zhang W; Zhang M; Zhang F; Xiao JQ; Yin Q; Zhuge YZ
Zhonghua Gan Zang Bing Za Zhi; 2021 Jan; 29(1):46-53. PubMed ID: 33541023
[No Abstract] [Full Text] [Related]
4. Transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome.
Zhou CZ; Wang RF; Lv WF; Fu YQ; Cheng DL; Zhu YJ; Hou CL; Ye XJ
World J Gastroenterol; 2020 Jun; 26(24):3472-3483. PubMed ID: 32655270
[TBL] [Abstract][Full Text] [Related]
5. Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt.
Xiao J; Tu J; Zhang H; Zhang F; Zhang W; Xu H; Yin Q; Yang J; Han H; Wang Y; Zhang B; Peng C; Zou X; Zhang M; Zhuge Y
Hepatol Int; 2021 Jun; 15(3):720-729. PubMed ID: 33507485
[TBL] [Abstract][Full Text] [Related]
6. Transjugular Intrahepatic Portosystemic Shunt Benefits for Hepatic Sinusoidal Obstruction Syndrome Associated with Consumption of Gynura Segetum: a Propensity Score-Matched Analysis.
Li S; Li Y; Zhou C; Li H; Chen C; Peng C; Wang T; Liu F; Xiao J; Shi L
Cardiovasc Intervent Radiol; 2023 Jul; 46(7):931-942. PubMed ID: 37225971
[TBL] [Abstract][Full Text] [Related]
7. Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.
Zhang L; Li Q; Makamure J; Zhao D; Liu Z; Zheng C; Liang B
BMC Gastroenterol; 2021 Jan; 21(1):26. PubMed ID: 33423668
[TBL] [Abstract][Full Text] [Related]
8. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Zhuge Y; Liu Y; Xie W; Zou X; Xu J; Wang J;
J Gastroenterol Hepatol; 2019 Apr; 34(4):634-642. PubMed ID: 30669184
[TBL] [Abstract][Full Text] [Related]
9. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome.
Gao H; Ruan JQ; Chen J; Li N; Ke CQ; Ye Y; Lin G; Wang JY
Drug Des Devel Ther; 2015; 9():4861-8. PubMed ID: 26346783
[TBL] [Abstract][Full Text] [Related]
10. Transjugular intrahepatic portosystemic shunt for pyrrolidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective cohort study.
Huang T; Zhang X; Yan K; Lou D; He Y; Dai S; Zheng D; Chen P; Wu F; Gu L
Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):1004-1011. PubMed ID: 37395216
[TBL] [Abstract][Full Text] [Related]
11. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.
Yang XQ; Ye J; Li X; Li Q; Song YH
World J Gastroenterol; 2019 Jul; 25(28):3753-3763. PubMed ID: 31391770
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease.
Zhuge YZ; Wang Y; Zhang F; Zhu CK; Zhang W; Zhang M; He Q; Yang J; He J; Chen J; Zou XP
Liver Int; 2018 Oct; 38(10):1867-1874. PubMed ID: 29297975
[TBL] [Abstract][Full Text] [Related]
13. Prognostic risk factors for patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids.
Du X; Liu Z; Yu H; Wang Y; Zou Z; Wei H; Liang J; Yang D; Liu Y; Zhang J; Pan CQ
Medicine (Baltimore); 2023 Aug; 102(32):e34698. PubMed ID: 37565875
[TBL] [Abstract][Full Text] [Related]
14. Tusanqi and hepatic sinusoidal obstruction syndrome.
Wang JY; Gao H
J Dig Dis; 2014 Mar; 15(3):105-7. PubMed ID: 24528632
[TBL] [Abstract][Full Text] [Related]
15. Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study.
Wang C; Wang Y; Zhao J; Yang C; Zhu X; Niu H; Sun J; Xiong B
Heliyon; 2024 Jan; 10(1):e23455. PubMed ID: 38163189
[TBL] [Abstract][Full Text] [Related]
16. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids.
Gao H; Li N; Wang JY; Zhang SC; Lin G
J Dig Dis; 2012 Jan; 13(1):33-9. PubMed ID: 22188914
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological analysis of 16 cases of pyrrolizidine alkaloids-associated hepatic sinusoidal obstruction syndrome].
Li YS; Bao J; Xu Y; Wang TL
Zhonghua Gan Zang Bing Za Zhi; 2020 Apr; 28(4):332-337. PubMed ID: 32403886
[No Abstract] [Full Text] [Related]
18. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans.
Yang M; Ruan J; Gao H; Li N; Ma J; Xue J; Ye Y; Fu PP; Wang J; Lin G
Arch Toxicol; 2017 Dec; 91(12):3913-3925. PubMed ID: 28620673
[TBL] [Abstract][Full Text] [Related]
19. Direct Intrahepatic Portocaval Shunt for Sinusoidal Obstruction Syndrome Associated with Hepatotoxicity of Pyrrolizidine Alkaloids.
Luo S; Chu J; Huang H; Yao K
Biomed Res Int; 2018; 2018():9804582. PubMed ID: 30009181
[TBL] [Abstract][Full Text] [Related]
20. Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function.
Guo T; Li X; Yang X; Kong X; Liu H; Bai T; Xu K; Ye J; Song Y
Sci Rep; 2019 Feb; 9(1):1231. PubMed ID: 30718698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
